SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-025564
Filing Date
2023-03-31
Accepted
2023-03-31 16:47:57
Documents
13
Period of Report
2023-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea176222-8k_abvcbio.htm   iXBRL 8-K 28174
2 PRESS RELEASE ea176222ex99-1_abvcbio.htm EX-99.1 100772
  Complete submission text file 0001213900-23-025564.txt   314380

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abvc-20230331.xsd EX-101.SCH 2965
4 XBRL LABEL FILE abvc-20230331_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE abvc-20230331_pre.xml EX-101.PRE 22363
7 EXTRACTED XBRL INSTANCE DOCUMENT ea176222-8k_abvcbio_htm.xml XML 3494
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

IRS No.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 23788710
SIC: 2834 Pharmaceutical Preparations